HDI Versus Chemotherapy as Systemic Adjuvant Therapy for Resected Mucosal Melanoma

Inclusion Criteria: 1. Age more than 18 years; 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; 3. Pathologically confirmed diagnosis of mucosal melanoma; 4. Completely resected primary tumor (once regional lymph nodes were involved, diagnosed by clinical or imaging examinations, lymphadenectomy was conducted); 5. No prior systemic adjuvant therapy or regional radiotherapy; 6. No evidence of distant metastatic disease evaluated by means of lymph nodes ultrasound, endoscopy, and ultrasound of anorectum and genitourinary tract, single-photon emission computed tomography (CT) of bone, and whole-body spiral CT or positron emission tomography-CT (PET-CT); 7. Normal bone marrow function; and adequate liver and renal function \[including white blood cell (WBC) count \> 3,000/mm\^3;absolute neutrophil count \> 1,500/mm\^3; platelets \>100,000/mm\^3; serum creatinine less than two times of the upper limit of normal (ULN); bilirubin less than 1.5 times of ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 times of ULN; international normalized ratio less than 1.5 times of ULN; and partial thromboplastin time less than ULN\]. Exclusion Criteria: 1. Cutaneous melanoma or ocular melanoma or melanoma of unknown primary site; 2. Incomplete resection or primary tumor unable to be resected; 3. A second cancer diagnosis; 4. Definite medical history of cirrhoses of the liver or autoimmune diseases; 5. Severe depression; and pregnant or lactating female.